Overall, our findings highlight pRb as a novel target for VHL-mediated degradation and the VHL-pRb-SKIDA1 pathway as a potential therapeutic target in ccRCC treatment. This evidence concerns the gene RB1 and nonpapillary renal cell carcinoma.